The Business: A Portfolio of Mini-Monopolies
Stryker is a diversified MedTech giant that has effectively de-risked its revenue stream. No single product line accounts for more than 15% of total sales.
MedSurg & Neurotechnology: The "Utility" arm. These are the beds, lights, and power tools every hospital must have to function.
Orthopaedics: The "Ecosystem" arm. This is anchored by the Mako Robotic-Arm Assisted Technology.
The "Buffett" Moat (High Switching Costs): Once a surgeon spends years mastering the Mako robotic system for knee and hip replacements, they are highly unlikely to switch to a competitor. The system becomes the "operating system" of the surgeon's career. Furthermore, Stryker is deeply embedded in hospital procurement workflows, making them a "preferred vendor" that is difficult to dislodge.
Financials: The Quality of Earnings
Operating Margins: Adjusted operating margins have expanded to ~26.3% in 2025/26.
Return on Equity (ROE): Consistently in the 15–18% range.
Owner Earnings: Stryker generates significant Free Cash Flow (FCF), which it uses to fund a "Serial Acquisition" strategy that Warren would recognize as a disciplined version of our own decentralized growth model.
Management & Capital Allocation
Kevin Lobo (CEO since 2012) has executed a "Buffett-style" playbook:
Strategic M&A: Acquisitions like Inari Medical (2025) and Vocera are not "diworsification." They are bolt-ons that leverage Stryker's existing sales force.
Dividend Discipline: 30+ years of consecutive dividend increases. While the yield is low (~1.1%), the payout ratio is conservative, leaving plenty of "dry powder" for reinvestment.
The Verdict: Is there a Margin of Safety?
Stryker is currently trading at $329.35, or roughly 24x adjusted forward earnings.
The Bear Case: At 24x, we are paying a "fair price for a wonderful business." It is not a "bargain" in the traditional sense. It lacks the 50%+ margins of the financial exchanges we discussed previously.
The Bull Case: Unlike the exchanges, Stryker has a massive demographic tailwind. As the "Silver Tsunami" (aging population) hits its peak, the volume of knee, hip, and vascular procedures is a statistical certainty.
While Stryker is a superior business, its current valuation lacks the Margin of Safety.
We should keep Stryker on our "Watch List." If a broader market correction brings the P/E down to the 18–20x range (approximately $260–$280), we should move aggressively. It is a "Forever Business
Comments